Results 201 to 210 of about 223,105 (281)

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden   +3 more
wiley   +1 more source

Liver injury in post-acute COVID-19 syndrome: A systematic review and meta-analysis of early observational studies. [PDF]

open access: yesCan Liver J
Mundra P   +6 more
europepmc   +1 more source

Drivers of bat researchers’ intent to adopt field hygiene practices

open access: yesConservation Biology, EarlyView.
Abstract Infectious disease is a growing threat to wildlife, with zoonotic transmission most likely at the human–wildlife interface. One underappreciated activity at this interface is fieldwork with wild animals, but associated risks can be mitigated through field hygiene (FH) practices, such as using personal protective equipment and other appropriate
Joanna L. Coleman   +6 more
wiley   +1 more source

Post-COVID-19 Condition and Pulmonary Embolism

open access: yes
Hsien-Po Huang,1,2 Hsiu-Wen Wang,1 Chia-Hsin Cheng,1 Yi-Shan Chang,1 Ting-Kuang Yeh,1,2 Wei-Hsuan Huang,1 Chia-Wei Liu,1 Chih-Hung Chang,6 Po-Yu Liu,1– 5 Yu-Chun Yen,7 Chien-Hao Tseng1 1Division of Infectious Diseases, Department of Internal Medicine ...
Tseng CH   +10 more
core  

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo   +4 more
wiley   +1 more source

Novel Clinical, Immunological, and Metabolic Features Associated with Persistent Post-Acute COVID-19 Syndrome. [PDF]

open access: yesInt J Mol Sci
Santana-de Anda K   +13 more
europepmc   +1 more source

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy